CanSino Biologics Inc.

HKSE 6185.HK

CanSino Biologics Inc. Shareholders' Equity for the year ending December 31, 2023: USD 742.93 M

CanSino Biologics Inc. Shareholders' Equity is USD 742.93 M for the year ending December 31, 2023, a -24.03% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • CanSino Biologics Inc. Shareholders' Equity for the year ending December 31, 2022 was USD 977.87 M, a -22.28% change year over year.
  • CanSino Biologics Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 1.26 B, a 35.29% change year over year.
  • CanSino Biologics Inc. Shareholders' Equity for the year ending December 31, 2020 was USD 930.05 M, a 340.44% change year over year.
  • CanSino Biologics Inc. Shareholders' Equity for the year ending December 31, 2019 was USD 211.17 M, a 189.12% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
SV Wall Street
HKSE: 6185.HK

CanSino Biologics Inc.

CEO Dr. Xuefeng Yu Ph.D.
IPO Date March 28, 2019
Location China
Headquarters 401-420, Biomedical Park
Employees 1,494
Sector Health Care
Industries
Description

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Similar companies

2013.HK

Weimob Inc.

USD 0.29

3.60%

2196.HK

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

USD 1.72

0.73%

1801.HK

Innovent Biologics, Inc.

USD 4.24

1.99%

9926.HK

Akeso, Inc.

USD 7.68

-4.49%

2269.HK

WuXi Biologics (Cayman) Inc.

USD 2.37

1.19%

StockViz Staff

January 31, 2025

Any question? Send us an email